Skip to Content

Zecuity Approval History

FDA Approved: Yes (Discontinued) (First approved January 17, 2013)
Brand name: Zecuity
Generic name: sumatriptan
Dosage form: Transdermal Patch
Company: Teva Pharmaceuticals USA, Inc.
Treatment for: Migraine

Marketing Status: Discontinued

Zecuity (sumatriptan iontophoretic transdermal system) is a serotonin (5HT) 1b/1d receptor agonist (triptan) indicated for the acute treatment of migraine.

Development History and FDA Approval Process for Zecuity

DateArticle
Jan 18, 2013Approval NuPathe's Zecuity Approved by the FDA for the Acute Treatment of Migraine
Aug 30, 2011FDA Requests Additional Information Regarding NuPathe's Migraine Patch in Complete Response Letter

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide